Current opinion in rheumatology · 2019
Treatment of juvenile idiopathic arthritis: what's new?
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Giancane Gabriella, Ruperto Nicolino, Paediatric Rheumatology International Trials Organisation (PRINTO)
Аннотация
PURPOSE OF REVIEW: The present review highlights the advances in disease outcome achieved with currently available biologic medications and future perspectives for JIA management.
RECENT FINDINGS: In the last two decades, the management of juvenile idiopathic arthritis (JIA) has been revolutionized by appropriate legislative initiatives, the existence of very large collaborative networks and the increased availability of the novel biologic medications.
SUMMARY: A more rational approach to the management of JIA is being fostered by the recent publication of therapeutic recommendations, consensus treatment plans and for a treat-to-target strategy.
RECENT FINDINGS: In the last two decades, the management of juvenile idiopathic arthritis (JIA) has been revolutionized by appropriate legislative initiatives, the existence of very large collaborative networks and the increased availability of the novel biologic medications.
SUMMARY: A more rational approach to the management of JIA is being fostered by the recent publication of therapeutic recommendations, consensus treatment plans and for a treat-to-target strategy.